how's it going? Hope you and the family are well!!!
I wrote up a blog post on this "new breakthrough" which looks a lot like Copaxone, and was tested on mice with EAE---not humans with MS.
In reading the paper, we learn that this new "breakthrough" is remarkebly reminiscent of Copaxone treatment, in which killer T cells are said to be modulated to helpful T cells by means of exposing them to an antigen (in Copaxone's case, that's a mimic of the proteins found in myelin basic protein---glatiramer acetate.) This particular "new breakthrough hope" therapy is going after CD4+ T cells, using injected peptide epitopes, rather than intact antigens--which are said to be "more effective."
The whole paper is available in Nature-- a bit less WOW! than the press releases--http://www.nature.com/ncomms/2014/14090 ... s5741.html
CD4+ t cells (the target) are also found to be inflammatory in stroke and reperfusion injury. They are certainly not unique to MS----and they are not always related to "autoimmune" disease. They are activated in reperfusion, hypoperfusion, and ischemic situations...which always makes me wonder why the immunologists don't work with vascular researchers. But those silos are pretty far apart.http://ccsviinms.blogspot.com/2014/09/m ... witch.html
hope this all helps explain it--
Hyperbole, once again.